Prednisolone attenuates improvement of cardiac and skeletal contractile function and histopathology by lisinopril and spironolactone in the mdx mouse model of Duchenne muscular dystrophy.

Duchenne muscular dystrophy (DMD) is an inherited disease that causes striated muscle weakness. Recently, we showed therapeutic effects of the combination of lisinopril (L), an angiotensin converting enzyme (ACE) inhibitor, and spironolactone (S), an aldosterone antagonist, in mice lacking dystrophi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Paul M L Janssen, Jason D Murray, Kevin E Schill, Neha Rastogi, Eric J Schultz, Tam Tran, Subha V Raman, Jill A Rafael-Fortney
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2014
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/ab56521f9d8d4acfa90e1e22a0eee762
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ab56521f9d8d4acfa90e1e22a0eee762
record_format	dspace
spelling	oai:doaj.org-article:ab56521f9d8d4acfa90e1e22a0eee7622021-11-18T08:32:39ZPrednisolone attenuates improvement of cardiac and skeletal contractile function and histopathology by lisinopril and spironolactone in the mdx mouse model of Duchenne muscular dystrophy.1932-620310.1371/journal.pone.0088360https://doaj.org/article/ab56521f9d8d4acfa90e1e22a0eee7622014-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24551095/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203Duchenne muscular dystrophy (DMD) is an inherited disease that causes striated muscle weakness. Recently, we showed therapeutic effects of the combination of lisinopril (L), an angiotensin converting enzyme (ACE) inhibitor, and spironolactone (S), an aldosterone antagonist, in mice lacking dystrophin and haploinsufficient for utrophin (utrn(+/-);mdx, het mice); both cardiac and skeletal muscle function and histology were improved when these mice were treated early with LS. It was unknown to what extent LS treatment is effective in the most commonly used DMD murine model, the mdx mouse. In addition, current standard-of-care treatment for DMD is limited to corticosteroids. Therefore, potentially useful alternative or additive drugs need to be both compared directly to corticosteroids and tested in presence of corticosteroids. We evaluated the effectiveness of this LS combination in the mdx mouse model both compared with corticosteroid treatment (prednisolone, P) or in combination (LSP). We tested the additional combinatorial treatment containing the angiotensin II receptor blocker losartan (T), which is widely used to halt and treat the developing cardiac dysfunction in DMD patients as an alternative to an ACE inhibitor. Peak myocardial strain rate, assessed by magnetic resonance imaging, showed a negative impact of P, whereas in both diaphragm and extensor digitorum longus (EDL) muscle contractile function was not significantly impaired by P. Histologically, P generally increased cardiac damage, estimated by percentage area infiltrated by IgG as well as by collagen staining. In general, groups that only differed in the presence or absence of P (i.e. mdx vs. P, LS vs. LSP, and TS vs. TSP) demonstrated a significant detrimental impact of P on many assessed parameters, with the most profound impact on cardiac pathology.Paul M L JanssenJason D MurrayKevin E SchillNeha RastogiEric J SchultzTam TranSubha V RamanJill A Rafael-FortneyPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 9, Iss 2, p e88360 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Paul M L Janssen Jason D Murray Kevin E Schill Neha Rastogi Eric J Schultz Tam Tran Subha V Raman Jill A Rafael-Fortney Prednisolone attenuates improvement of cardiac and skeletal contractile function and histopathology by lisinopril and spironolactone in the mdx mouse model of Duchenne muscular dystrophy.
description	Duchenne muscular dystrophy (DMD) is an inherited disease that causes striated muscle weakness. Recently, we showed therapeutic effects of the combination of lisinopril (L), an angiotensin converting enzyme (ACE) inhibitor, and spironolactone (S), an aldosterone antagonist, in mice lacking dystrophin and haploinsufficient for utrophin (utrn(+/-);mdx, het mice); both cardiac and skeletal muscle function and histology were improved when these mice were treated early with LS. It was unknown to what extent LS treatment is effective in the most commonly used DMD murine model, the mdx mouse. In addition, current standard-of-care treatment for DMD is limited to corticosteroids. Therefore, potentially useful alternative or additive drugs need to be both compared directly to corticosteroids and tested in presence of corticosteroids. We evaluated the effectiveness of this LS combination in the mdx mouse model both compared with corticosteroid treatment (prednisolone, P) or in combination (LSP). We tested the additional combinatorial treatment containing the angiotensin II receptor blocker losartan (T), which is widely used to halt and treat the developing cardiac dysfunction in DMD patients as an alternative to an ACE inhibitor. Peak myocardial strain rate, assessed by magnetic resonance imaging, showed a negative impact of P, whereas in both diaphragm and extensor digitorum longus (EDL) muscle contractile function was not significantly impaired by P. Histologically, P generally increased cardiac damage, estimated by percentage area infiltrated by IgG as well as by collagen staining. In general, groups that only differed in the presence or absence of P (i.e. mdx vs. P, LS vs. LSP, and TS vs. TSP) demonstrated a significant detrimental impact of P on many assessed parameters, with the most profound impact on cardiac pathology.
format	article
author	Paul M L Janssen Jason D Murray Kevin E Schill Neha Rastogi Eric J Schultz Tam Tran Subha V Raman Jill A Rafael-Fortney
author_facet	Paul M L Janssen Jason D Murray Kevin E Schill Neha Rastogi Eric J Schultz Tam Tran Subha V Raman Jill A Rafael-Fortney
author_sort	Paul M L Janssen
title	Prednisolone attenuates improvement of cardiac and skeletal contractile function and histopathology by lisinopril and spironolactone in the mdx mouse model of Duchenne muscular dystrophy.
title_short	Prednisolone attenuates improvement of cardiac and skeletal contractile function and histopathology by lisinopril and spironolactone in the mdx mouse model of Duchenne muscular dystrophy.
title_full	Prednisolone attenuates improvement of cardiac and skeletal contractile function and histopathology by lisinopril and spironolactone in the mdx mouse model of Duchenne muscular dystrophy.
title_fullStr	Prednisolone attenuates improvement of cardiac and skeletal contractile function and histopathology by lisinopril and spironolactone in the mdx mouse model of Duchenne muscular dystrophy.
title_full_unstemmed	Prednisolone attenuates improvement of cardiac and skeletal contractile function and histopathology by lisinopril and spironolactone in the mdx mouse model of Duchenne muscular dystrophy.
title_sort	prednisolone attenuates improvement of cardiac and skeletal contractile function and histopathology by lisinopril and spironolactone in the mdx mouse model of duchenne muscular dystrophy.
publisher	Public Library of Science (PLoS)
publishDate	2014
url	https://doaj.org/article/ab56521f9d8d4acfa90e1e22a0eee762
work_keys_str_mv	AT paulmljanssen prednisoloneattenuatesimprovementofcardiacandskeletalcontractilefunctionandhistopathologybylisinoprilandspironolactoneinthemdxmousemodelofduchennemusculardystrophy AT jasondmurray prednisoloneattenuatesimprovementofcardiacandskeletalcontractilefunctionandhistopathologybylisinoprilandspironolactoneinthemdxmousemodelofduchennemusculardystrophy AT kevineschill prednisoloneattenuatesimprovementofcardiacandskeletalcontractilefunctionandhistopathologybylisinoprilandspironolactoneinthemdxmousemodelofduchennemusculardystrophy AT neharastogi prednisoloneattenuatesimprovementofcardiacandskeletalcontractilefunctionandhistopathologybylisinoprilandspironolactoneinthemdxmousemodelofduchennemusculardystrophy AT ericjschultz prednisoloneattenuatesimprovementofcardiacandskeletalcontractilefunctionandhistopathologybylisinoprilandspironolactoneinthemdxmousemodelofduchennemusculardystrophy AT tamtran prednisoloneattenuatesimprovementofcardiacandskeletalcontractilefunctionandhistopathologybylisinoprilandspironolactoneinthemdxmousemodelofduchennemusculardystrophy AT subhavraman prednisoloneattenuatesimprovementofcardiacandskeletalcontractilefunctionandhistopathologybylisinoprilandspironolactoneinthemdxmousemodelofduchennemusculardystrophy AT jillarafaelfortney prednisoloneattenuatesimprovementofcardiacandskeletalcontractilefunctionandhistopathologybylisinoprilandspironolactoneinthemdxmousemodelofduchennemusculardystrophy
_version_	1718421702911721472

Prednisolone attenuates improvement of cardiac and skeletal contractile function and histopathology by lisinopril and spironolactone in the mdx mouse model of Duchenne muscular dystrophy.

Ejemplares similares